Mode
Text Size
Log in / Sign up
Phase 2 N=16 Treatment

Pharmacokinetics of Advantage Anti-Caries Varnish

Dental Caries

Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcome: Primary: Observed Iodine Tmax — 1.7 hours

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Anti-caries varnish (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Advantage Silver Dental Arrest, LLC
Primary completion
Feb 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Observed Iodine Tmax
1.7
PRIMARY
Observed Iodine Cmax
111
PRIMARY
Observed Iodine Baseline-Corrected Cmax
57
PRIMARY
Observed Iodine Baseline-Corrected AUC
539
PRIMARY
Observed Iodine Total Urinary Recovery
1.26
PRIMARY
Iodine t1/2
5.5
PRIMARY
Observed Fluoride Tmax
0.8
PRIMARY
Observed Fluoride Cmax
76
PRIMARY
Observed Fluoride Baseline-Corrected Cmax
60
PRIMARY
Observed Fluoride AUC
703
PRIMARY
Observed Fluoride Baseline-Corrected AUC
315
PRIMARY
Fluoride t1/2
3.1
PRIMARY
Observed Fluoride Total Urinary Recovery
2.51

Summary

The study aim is to characterize the kinetics of iodine and fluoride following topical application of a combined PVP-I and NaF anti-dental caries varnish in healthy adults.

Eligibility Criteria

Inclusion Criteria

  • Healthy adults 18 y and older, at least 20 teeth, not taking prescription or OTC medications.

Exclusion Criteria

  • Pregnant, weighed less than 110 pounds, had oral mucositis, ulcerative lesions, sensitivity to shellfish or iodine or fluoride varnish, or had known hypothyroidism, hyperthyroidism, dermatitis herpetiformis, hypocomplementemic vasculitis, nodular thread with heart disease, multi nodular goiter, Graves disease, or autoimmune thyroiditis
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04183231). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search